The pharmaceutical company that supplies Ozempic, Novo Nordisk, has recently advised us and the Ozempic Medicine Shortage Action Group (MSAG) that supply will continue to be limited until 31 December 2025.
Ozempic is a semaglutide product approved for the management of type 2 diabetes not adequately managed by other medications, in conjunction with diet and exercise.
Click on the link for more information: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/update-ozempic-supply-remain-limited-2025